U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07504029) titled 'Human Clinical Trial Evaluating the Blood Glucose-Regulating Effects of Momordica Charantia Peptides' on March 25.
Brief Summary: Prediabetes is a metabolic condition characterized by elevated blood glucose levels that are higher than normal but below the diagnostic threshold for diabetes. Early intervention to improve glycemic control may help delay the progression to type 2 diabetes. Momordica charantia (bitter melon) peptides have been reported to possess potential glucose-regulating effects.
This study aims to evaluate the effects of BmpP(R) bitter melon peptide supplementation on glycemic control in adults with prediabetes. Th...